START Midwest team has successfully dosed the first patient in the first QTX3046 Phase I trial

The START Center for Cancer Research shared on LinkedIn:

“We are proud to announce that the first patient in the Quanta Therapeutics QTX3046 Phase I trial has been successfully dosed at START Midwest. This study aims to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab in patients with KRAS G12D mutations. We’re also excited to share that this study is open at our START San Antonio site, highlighting our commitment to advancing cancer research across communities everywhere.

To learn more about the QTX3046 study, please visit here.”

Source: The START Center for Cancer Research/LinkedIn

.